文献速递妇产影像US

基于超声与游离DNA的一孕早期风险筛查与联合筛查的随机对照试验

First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-03-04

该随机对照试验将孕11–13周超声正常(NT≤3.5 mm且无胎儿缺陷)的单胎孕妇随机分为两组,分别采用英国胎儿医学基金会最新算法的孕早期联合筛查(FTCS)和超声联合游离DNA(cfDNA)分析进行非整倍体风险评估。超声+cfDNA组21三体风险均未超过1:100(95%CI 0.0–0.5%),FTCS组有2.5%(95%CI 1.5–3.9%)风险超过1:100,前者假阳性率显著降低,且该方案无需母血清游离β-hCG和妊娠相关血浆蛋白A。

要点

  • 孕11–13周超声正常(NT≤3.5 mm、无胎儿缺陷)者,超声+cfDNA方案21三体风险均未超过1:100(95%CI 0.0–0.5%)。
  • FTCS组21三体风险中位数为1:3787,17例风险高于1:100,占该组2.5%(95%CI 1.5–3.9%)。
  • 超声+cfDNA方案可省去母血清游离β-hCG和妊娠相关血浆蛋白A检测。

核心结论

  • 包含详细超声检查及NT测量、随后行cfDNA检测的孕早期21三体风险评估,与FTCS相比假阳性率显著降低,且无需母血清游离β-hCG和妊娠相关血浆蛋白A。

研究设计与样本

  • 随机对照试验,2015年10月至2016年12月纳入1518例单胎妊娠孕妇,排除31例(2.0%)NT>3.5 mm和/或胎儿缺陷、87例拒绝随机化及24例胎儿死亡和失访后,FTCS组与超声+cfDNA组各随机688例。

关键影像表现/征象

  • 超声+cfDNA组21三体风险中位数为1/10000,无病例风险高于1:100(95%CI 0.0–0.5%)。
  • FTCS组21三体风险中位数为1/3787,17例风险高于1:100,占该组2.5%(95%CI 1.5–3.9%)。
  • 两组母亲年龄、孕龄、体重和BMI、种族、辅助生殖使用及吸烟情况无差异。

诊断标准与关键数值

  • 假阳性定义为核型非21三体且21三体风险>1:100,不论风险计算方法。
  • FTCS基于英国胎儿医学基金会最新算法评估非整倍体风险。
  • 超声+cfDNA组在cfDNA分析无信息时加采一管血用于FTCS。

临床应用与阅片要点

  • 对孕11–13周超声正常(NT≤3.5 mm、无胎儿缺陷)者,作者认为包含详细超声及NT测量后行cfDNA检测的方案可显著降低21三体筛查假阳性率。
  • 作者指出该方案无需母血清游离β-hCG和妊娠相关血浆蛋白A用于胎儿非整倍体筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This was a randomized controlled trial to compare risk assessment by first-trimester combined screening (FTCS) with an approach that combines a detailed ultrasound examination at 11-13 weeks' gestation and cell-free DNA (cfDNA) analysis.

METHODS: Pregnant women with a normal first-trimester ultrasound examination at 11-13 weeks' gestation (fetal nuchal translucency (NT) ≤ 3.5 mm and no fetal defects) were randomized into one of two groups. In the first group, risk of aneuploidy was assessed using FTCS based on the most recent UK Fetal Medicine Foundation algorithm. In the second group, risk assessment was based on ultrasound findings and cfDNA analysis. An additional tube of blood was collected for FTCS in case the cfDNA analysis was uninformative. Primary outcome was false-positive rate in screening for trisomy 21. A case was considered false positive if the karyotype was not trisomy 21 and if the risk for trisomy 21 was >1:100, irrespective of the method of risk calculation. Results were compared using 95% CIs using the Clopper-Pearson method.

RESULTS: Between October 2015 and December 2016, 1518 women with singleton pregnancy underwent first-trimester screening. Thirty-one (2.0%) pregnancies were not eligible for randomization due to increased NT (> 3.5 mm) and/or fetal defect. After exclusion of women who declined randomization (n = 87) and cases of fetal death and loss to follow-up (n = 24), 688 pregnancies were randomized into the FTCS arm and 688 into the ultrasound + cfDNA analysis arm. There were no differences in maternal and gestational age, maternal weight and BMI, ethnicity, use of assisted reproduction and cigarette smoking between the two arms. In the ultrasound + cfDNA analysis arm, median risk for trisomy 21 was 1 in 10 000. None of the cases had a risk above 1: 100 (95% CI, 0.0-0.5%). In the FTCS arm, the median risk for trisomy 21 was 1 in 3787 and in 17 cases, the risk was higher than 1:100, which corresponds to 2.5% (95% CI, 1.5-3.9%) of the FTCS study-arm population.

CONCLUSION: Our study has shown that first-trimester risk assessment for trisomy 21 that includes a detailed ultrasound examination as well as NT measurement and is followed by cfDNA testing is associated with a significant reduction in the false-positive rate compared with FTCS. This approach obviates the need for maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A in screening for fetal aneuploidy. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kagan KO, Sroka F, Sonek J, et al. First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial. Ultrasound Obstet Gynecol. 2018. PMID: 28925570. doi:10.1002/uog.18905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。